Detalles de la búsqueda
1.
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Lancet;
403(10424): 379-390, 2024 Jan 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38109916
2.
Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease.
Am J Nephrol;
55(2): 262-272, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-37903483
3.
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial.
Diabetes Obes Metab;
26(6): 2128-2138, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38497241
4.
Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study.
Eur Heart J;
44(13): 1157-1166, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36691956
5.
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
Kidney Int;
104(6): 1219-1226, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37657768
6.
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
Am J Kidney Dis;
82(1): 84-96.e1, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36889425
7.
Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease.
Cardiovasc Diabetol;
22(1): 251, 2023 09 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37716952
8.
Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial.
Diabetes Obes Metab;
25(8): 2218-2226, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37232058
9.
The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab;
25(12): 3724-3735, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37671609
10.
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
Diabetes Obes Metab;
25(8): 2151-2162, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37161691
11.
Longitudinal relationship between albuminuria in infancy and childhood.
Pediatr Nephrol;
38(8): 2897-2900, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36705757
12.
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
Circulation;
143(18): 1735-1749, 2021 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33554616
13.
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
N Engl J Med;
380(24): 2295-2306, 2019 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-30990260
14.
Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
Am J Kidney Dis;
79(2): 244-256.e1, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34029680
15.
Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study.
Diabetes Obes Metab;
24(8): 1429-1438, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35491532
16.
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
J Am Soc Nephrol;
32(11): 2900-2911, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34551995
17.
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program.
Diabetologia;
64(11): 2402-2414, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34448033
18.
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
Stroke;
52(5): 1545-1556, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33874750
19.
New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction.
Kidney Int;
99(2): 346-349, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33144213
20.
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
Kidney Int;
99(4): 999-1009, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33316282